Prospectus
Filed with ASX · · 32 pages · English
On 6ix: 6ix.com/news/prospectus-226
For the offer of a pro-rata non-renounceable entitlement issue of up to approximately 79,228,096 Entitlement Options, on the basis of 1 Entitlement Option for every 4 Shares held by Eligible Shareholders at an issue price of 1 cent per Entitlement Option, to raise up to approximately $792,281 Offer closes at 5:00pm WST on 2 November 2021 This document is a transaction specific prospectus issued in
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Entitlement Options Offer
- Epichem Completes Final Loan Repayment
- Epichem Completes Build of OHD Benchtop Flow Reactor
- Monepantel and monepantel sulfone COVID-19 anti-viral update
- PharmAust and WEHI to Investigate HTLV-1 Viral Infections
Later from Neurizon Therapeutics
- Following Extension of Survival, PAA Prepares Phase 3 Trial
- MPL Manufacturing and Human Trials Update
- Canine phase 2b cancer trial expands to New Zealand
- MND & COVID-19 Phase 1 Clinical Trials On-Track
- Demonstration batch of smaller size MPL tablets completed
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics